September 21, 2022
UCB Japan said on September 20 that its investigational anti-epileptic agent brivaracetam achieved the primary endpoint in an Asian PIII study including Japan for the treatment of epilepsy patients with partial-onset seizures. The placebo-controlled study investigated the efficacy and safety...read more